›

Hypertension: Treatments

Notes

Hypertension: Treatments

Sections




Overview

Antihypertensives aim to reduce cardiac output and/or total peripheral resistance.
– For a review of how cardiac output and total peripheral resistance, please see our tutorial on hypertension pathophysiology.

Lowering blood pressure in hypertensive patients reduces their risk of cardiovascular disease and cerebrovascular events.
– Recent guidelines recommend a target blood pressure of less than 130/80 mmHg.

The following lifestyle modifications are typically suggested:
– Changes in diet, increased physical activity, stress reduction, smoking and alcohol cessation or reduction, and weight loss.

DASH:
Dietary changes to reduce hypertension are encapsulated by the Dietary Approaches to Stop Hypertension (DASH) plan, which recommends reductions in sodium and emphasizes whole grains, fruits, vegetables, low-fat dairy, fish, poultry, and legumes, nuts, and seeds.

In many individuals, however, lifestyle modifications are inadequate or even inappropriate for reducing blood pressure; these patients will need antihypertensive medications.

Initial treatment may rely on a single medication, depending on the stage of hypertension.

However, many patients ultimately require two or more drugs with complementary actions to reach their target blood pressure.

Individuals vary in their responses to antihypertensive medications, and that specific recommendations are made for some populations.
– For example, African Americans, the elderly, and patients with certain medical conditions may respond differently to an antihypertensive drug than other populations.

**Resistant hypertension is when an individual's blood pressure remains elevated above the target goal, despite concurrently using three or more antihypertensive medications, including a diuretic.

Thiazide and thiazide-like diuretics

These drugs act on the distal convoluted tubule of the nephron to prohibit sodium and water reabsorption; sodium and water are excreted in the urine, so blood volume and blood pressure are reduced.

Often a first line choice, particularly in salt-sensitive individuals

They are associated with hypokalemia.

Chronic use causes vasodilation, which also contributes to reduction in blood pressure; the exact mechanism by which these diuretics cause vasodilation is uncertain.

Renin-Angiotensin System Inhibitors

Two drugs block the actions of angiotensin II, which is a powerful vasoconstrictor that also triggers the release of other blood pressure mediators, including aldosterone.

We show the renin-angiotensin system:
– The liver releases angiotensinogen.
– The kidneys release renin, which transforms angiotensinogen to angiotensin I.
– Then, as angiotensin I circulates in the blood, especially in the pulmonary blood, it encounters angiotensin-converting enzyme (ACE), which is released from vascular endothelial cells.
– Angiotensin converting enzyme, as its name suggests, converts angiotensin I to angiotensin II.
– Angiotensin II binds with arterial receptors and induces vasoconstriction.

Angiotensin-converting enzyme inhibitors
ACE inhibitors prohibit the formation of angiotensin II by blocking the actions of angiotensin-converting enzyme.

  • First-line drugs.

Can cause hyperkalemia.

Angiotensin II also breaks down bradykinin, which is an important vasodilator; thus, angiotensin-converting enzyme inhibitors effectively increase bradykinin levels, which ultimately enhances vasodilation.
– We show that increased bradykinin is associated with cough and angioedema.

Angiotensin-receptor blockers
Block the arterial receptors for angiotensin II.

Like ACE inhibitors, they prevent angiotensin II from increasing blood pressure.

Also like ACE inhibitors, they are associated with hyperkalemia.

However, since they don't prohibit the formation of angiotensin II, they don't effect bradykinin, so patients don't experience cough and angioedema.

"Blockers" that act directly on heart/vasculuature

Calcium channel blockers prevent calcium binding:
In the heart, receptors are located at the sinoatrial and atrioventricular nodes, as well as in the cardiac tissue; thus, calcium channel blockers reduce conduction velocity, contractility, and heart rate.

In the vasculature, prevention of calcium blocking reduces vasoconstriction.

Calcium channels are considered a first line treatment, particularly for African Americans, in whom other antihypertensive drugs are often less effective.

Calcium channel blockers are associated with swelling in the lower extremities, rash, flushing, and dizziness.

Beta blockers prevent norepinephrine and epinephrine binding

In the heart, block receptors (similar to calcium channel blockers)

Third generation beta blockers also produce vasodilation.

Beta blockers also block renin secretion from the kidney, which blocks the formation of angiotensin II and elevates bradykinin levels.

Commonly reported side effects include fatigue, cold hands/feet, depression, sleep disturbances, and erectile dysfunction.

Furthermore, some beta blockers can trigger bronchospasm in patients with asthma and chronic obstructive pulmonary disease.

Alpha blockers prevent norepinephrine from binding
In the vasculature, this reduces vasoconstriction.
Orthostatic hypotension is common, particularly in the elderly.

Hypertension References

  • "2017 Guideline for High Blood Pressure in Adults." American College of Cardiology. Accessed March 12, 2019. http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2ften-points-to-remember%2f2017%2f11%2f09%2f11%2f41%2f2017-guideline-for-high-blood-pressure-in-adults.
  • Akbari, Pegah, and Arshia Khorasani-Zadeh. "Thiazide Diuretics." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2019. http://www.ncbi.nlm.nih.gov/books/NBK532918/.
  • Bloomfield, Dennis A, and Alex Park. "Decoding White Coat Hypertension." World Journal of Clinical Cases 5, no. 3 (March 16, 2017): 82–92. https://doi.org/10.12998/wjcc.v5.i3.82.
  • Bramham, Kate, Bethany Parnell, Catherine Nelson-Piercy, Paul T. Seed, Lucilla Poston, and Lucy C. Chappell. "Chronic Hypertension and Pregnancy Outcomes: Systematic Review and Meta-Analysis." BMJ 348 (April 15, 2014): g2301. https://doi.org/10.1136/bmj.g2301.
  • Briant, L. J. B., N. Charkoudian, and E. C. Hart. "Sympathetic Regulation of Blood Pressure in Normotension and Hypertension: When Sex Matters: Sex Differences in Sympathetic Regulation of Blood Pressure." Experimental Physiology 101, no. 2 (February 1, 2016): 219–29. https://doi.org/10.1113/EP085368.
  • Burkholder, Greer A., Ashutosh R. Tamhane, Monika M. Safford, Paul M. Muntner, Amanda L. Willig, James H. Willig, James L. Raper, Michael S. Saag, and Michael J. Mugavero. "Racial Disparities in the Prevalence and Control of Hypertension among a Cohort of HIV-Infected Patients in the Southeastern United States." PLoS ONE 13, no. 3 (March 29, 2018). https://doi.org/10.1371/journal.pone.0194940.
  • Calhoun, David A. "Aldosteronism and Hypertension." Clinical Journal of the American Society of Nephrology 1, no. 5 (September 1, 2006): 1039–45. https://doi.org/10.2215/CJN.01060306.
  • Calhoun, David A., Ernesto L. Schiffrin, and John M. Flack. "Resistant Hypertension: An Update." American Journal of Hypertension 32, no. 1 (January 1, 2019): 1–3. https://doi.org/10.1093/ajh/hpy156.
  • "Cardioselective Beta Blocker Use in Patients With Asthma." Medscape. Accessed March 25, 2019. http://www.medscape.com/viewarticle/464040.
  • Carretero Oscar A., and Oparil Suzanne. "Essential Hypertension." Circulation 101, no. 3 (January 25, 2000): 329–35. https://doi.org/10.1161/01.CIR.101.3.329.
  • Carthy, Elliott R. "Autonomic Dysfunction in Essential Hypertension: A Systematic Review." Annals of Medicine and Surgery 3, no. 1 (March 1, 2014): 2–7. https://doi.org/10.1016/j.amsu.2013.11.002.
  • Choi, Hoon Young, Hyeong Cheon Park, and Sung Kyu Ha. "Salt Sensitivity and Hypertension: A Paradigm Shift from Kidney Malfunction to Vascular Endothelial Dysfunction." Electrolytes & Blood Pressure : E & BP 13, no. 1 (June 2015): 7–16. https://doi.org/10.5049/EBP.2015.13.1.7.
  • "Clinical Significance of Endothelial Dysfunction in Essential Hypertension - ProQuest." Accessed March 13, 2019. https://search.proquest.com/openview/c2ce48078c1759aaa0aaac88e5f8aab1/1.pdf?pq-origsite=gscholar&cbl=326347.
  • Colafella, Katrina M. Mirabito, and Kate M. Denton. "Sex-Specific Differences in Hypertension and Associated Cardiovascular Disease." Nature Reviews Nephrology, January 30, 2018. https://doi.org/10.1038/nrneph.2017.189.
  • DeMarco, Vincent G., Annayya R. Aroor, and James R. Sowers. "The Pathophysiology of Hypertension in Patients with Obesity." Nature Reviews. Endocrinology 10, no. 6 (June 2014): 364–76. https://doi.org/10.1038/nrendo.2014.44.
  • Eibl, A. D., H. G. Predel, T. Sanders, and J. Zacher. "[Neuronal Blood Pressure Regulation]." Klinische Monatsblatter fur Augenheilkunde 236, no. 2 (February 2019): 145–49. https://doi.org/10.1055/a-0808-4843.
  • Esler Murray. "Sympathetic Nervous System Moves Toward Center Stage in Cardiovascular Medicine." Hypertension 63, no. 3 (March 1, 2014): e25–32. https://doi.org/10.1161/HYPERTENSIONAHA.113.02439.
    "Explore High Blood Pressure in the United States | 2018 Annual Report." America's Health Rankings. Accessed March 19, 2019. https://www.americashealthrankings.org/explore/annual/measure/Hypertension/state/ALL.
  • Feihl, François, Lucas Liaudet, Bernard Waeber, and Bernard I. Levy. "Hypertension: A Disease of the Microcirculation?" Hypertension 48, no. 6 (December 2006): 1012–17. https://doi.org/10.1161/01.HYP.0000249510.20326.72.
  • Felder, Robin A., Marquitta J. White, Scott M. Williams, and Pedro A. Jose. "Diagnostic Tools for Hypertension and Salt Sensitivity Testing." Current Opinion in Nephrology and Hypertension 22, no. 1 (January 2013): 65–76. https://doi.org/10.1097/MNH.0b013e32835b3693.
  • Frishman, William H. "Beta-Adrenergic Receptor Blockers in Hypertension: Alive and Well." Progress in Cardiovascular Diseases 59, no. 3 (November 2016): 247–52. https://doi.org/10.1016/j.pcad.2016.10.005.
  • Gkaliagkousi, Eugenia, Eleni Gavriilaki, Areti Triantafyllou, and Stella Douma. "Clinical Significance of Endothelial Dysfunction in Essential Hypertension." Current Hypertension Reports; Philadelphia 17, no. 11 (November 2015): 1–9. http://dx.doi.org.proxy.ulib.uits.iu.edu/10.1007/s11906-015-0596-3.
  • González, Jaime, Nicolás Valls, Roberto Brito, and Ramón Rodrigo. "Essential Hypertension and Oxidative Stress: New Insights." World Journal of Cardiology 6, no. 6 (June 26, 2014): 353–66. https://doi.org/10.4330/wjc.v6.i6.353.
  • Harvey, Adam, Augusto C. Montezano, and Rhian M. Touyz. "Vascular Biology of Ageing—Implications in Hypertension." Journal of Molecular and Cellular Cardiology 83 (June 2015): 112–21. https://doi.org/10.1016/j.yjmcc.2015.04.011.
  • Helmer, Allison. "A Review of ACE Inhibitors and ARBs in Black Patients With Hypertension," n.d., 9.
  • Herman, Linda L., and Khalid Bashir. "Angiotensin Converting Enzyme Inhibitors (ACEI)." In StatPearls. Treasure Island (FL): StatPearls Publishing, 2019. http://www.ncbi.nlm.nih.gov/books/NBK431051/.
  • Intengan, H. D., and E. L. Schiffrin. "Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis." Hypertension (Dallas, Tex.: 1979) 38, no. 3 Pt 2 (September 2001): 581–87.
  • Intengan, Hope D, and Ernesto L Schiffrin. "Vascular Remodeling in Hypertension," n.d., 7.
    Julius Stevo, Pascual Arturo V., Sannerstedt Rune, and Mitchell Charles. "Relationship Between Cardiac Output and Peripheral Resistance in Borderline Hypertension." Circulation 43, no. 3 (March 1, 1971): 382–90. https://doi.org/10.1161/01.CIR.43.3.382.
  • Kang, Kyu-Tae. "Endothelium-Derived Relaxing Factors of Small Resistance Arteries in Hypertension." Toxicological Research 30, no. 3 (September 2014): 141–48. https://doi.org/10.5487/TR.2014.30.3.141.
  • Kobzik, Alexander, and Michael R. Pinsky. "Arterial Blood Pressure Regulation." In Hemodynamic Monitoring, edited by Michael R. Pinsky, Jean-Louis Teboul, and Jean-Louis Vincent, 39–48. Lessons from the ICU. Cham: Springer International Publishing, 2019. https://doi.org/10.1007/978-3-319-69269-2_5.
  • Lechi, Alessandro. "The Obesity Paradox: Is It Really a Paradox? Hypertension." Eating and Weight Disorders - Studies on Anorexia, Bulimia and Obesity 22, no. 1 (March 1, 2017): 43–48. https://doi.org/10.1007/s40519-016-0330-4.
  • Lemarié, Catherine A., Pierre-Louis Tharaux, and Stéphanie Lehoux. "Extracellular Matrix Alterations in Hypertensive Vascular Remodeling." Journal of Molecular and Cellular Cardiology 48, no. 3 (March 2010): 433–39. https://doi.org/10.1016/j.yjmcc.2009.09.018.
  • Lloyd-Jones, Donald M., Pamela B. Morris, Christie M. Ballantyne, Kim K. Birtcher, David D. Daly, Sondra M. DePalma, Margo B. Minissian, Carl E. Orringer, and Sidney C. Smith. "2017 Focused Update of the 2016 ACC Expert Consensus Decision Pathway on the Role of Non-Statin Therapies for LDL-Cholesterol Lowering in the Management of
    Atherosclerotic Cardiovascular Disease Risk." Journal of the American College of Cardiology 70, no. 14 (October 2017): 1785–1822. https://doi.org/10.1016/j.jacc.2017.07.745.
  • Mayet, Jamil, and Alun Hughes. "Cardiac and Vascular Pathophysiology in Hypertension." Heart 89, no. 9 (September 2003): 1104–9.
  • McMaster William G., Kirabo Annet, Madhur Meena S., and Harrison David G. "Inflammation, Immunity, and Hypertensive End-Organ Damage." Circulation Research 116, no. 6 (March 13, 2015): 1022–33.
    https://doi.org/10.1161/CIRCRESAHA.116.303697.
  • Mosso Lorena, Carvajal Cristian, González Alexis, Barraza Adolfo, Avila Fernando, Montero Joaquín, Huete Alvaro, Gederlini Alessandra, and Fardella Carlos E. "Primary Aldosteronism and Hypertensive Disease." Hypertension 42, no. 2 (August 1, 2003): 161–65. https://doi.org/10.1161/01.HYP.0000079505.25750.11.
  • Mozaffarian, Dariush, Emelia J Benjamin, Alan S Go, Donna K Arnett, Michael J Blaha, Mary Cushman, Sandeep R Das, et al. "Heart Disease and Stroke Statistics—2016 Update," n.d., 323.
  • Mulvany, Michael J. "Small Artery Remodeling and Significance in the Development of Hypertension." Physiology 17, no. 3 (June 2002): 105–9. https://doi.org/10.1152/nips.01366.2001.
  • ———. "Structural Abnormalities of the Resistance Vasculature in Hypertension." Journal of Vascular Research 40, no. 6 (2003): 558–60. https://doi.org/10.1159/000075805.
  • Murthy, Meena, Thimo Kurz, and Kevin M. O'Shaughnessy. "WNK Signalling Pathways in Blood Pressure Regulation." Cellular and Molecular Life Sciences 74, no. 7 (April 1, 2017): 1261–80. https://doi.org/10.1007/s00018-016-2402-z.
  • Nakao Kazuhiro, Kuwahara Koichiro, Nishikimi Toshio, Nakagawa Yasuaki, Kinoshita Hideyuki, Minami Takeya, Kuwabara Yoshihiro, et al. "Endothelium-Derived C-Type Natriuretic Peptide Contributes to Blood Pressure Regulation by Maintaining Endothelial Integrity." Hypertension 69, no. 2 (February 1, 2017): 286–96. https://doi.org/10.1161/HYPERTENSIONAHA.116.08219.
    "NCHS Data on Racial and Ethnic Disparities," n.d., 2.
  • "New ACC/AHA High Blood Pressure Guidelines Lower Definition of Hypertension." American College of Cardiology. Accessed March 14, 2019. http%3a%2f%2fwww.acc.org%2flatest-in-cardiology%2farticles%2f2017%2f11%2f08%2f11%2f47%2fmon-5pm-bp-guideline-aha-2017.
    Oparil, Suzanne, Md M. Amin Zaman, and David A. Calhoun. "Pathogenesis of Hypertension." Annals of Internal Medicine, 2003, 761–776.
  • "Overview of Hypertension - Cardiovascular Disorders." Merck Manuals Professional Edition. Accessed March 12, 2019. https://www.merckmanuals.com/professional/cardiovascular-disorders/hypertension/overview-of-hypertension.
  • "Ovid: Vascular Remodeling in Hypertension: Roles of Apoptosis, Inflammation, and Fibrosis." Accessed March 14, 2019.
  • Piaditis, George, Athina Markou, Labrini Papanastasiou, Ioannis I. Androulakis, and Gregory Kaltsas. "PROGRESS IN ALDOSTERONISM: A Review of the Prevalence of Primary Aldosteronism in Pre-Hypertension and Hypertension." European Journal of Endocrinology 172, no. 5 (May 1, 2015): R191–203. https://doi.org/10.1530/EJE-14-0537.
  • Pilic, Leta, Charles R. Pedlar, and Yiannis Mavrommatis. "Salt-Sensitive Hypertension: Mechanisms and Effects of Dietary and Other Lifestyle Factors." Nutrition Reviews 74, no. 10 (October 1, 2016): 645–58. https://doi.org/10.1093/nutrit/nuw028.

vPioli, Mariana R, Alessandra MV Ritter, Ana Paula de Faria, and Rodrigo Modolo. "White Coat Syndrome and Its Variations: Differences and Clinical Impact." Integrated Blood Pressure Control 11 (November 8, 2018): 73–79. https://doi.org/10.2147/IBPC.S152761.

  • Puar, Troy Hai Kiat, Yingjuan Mok, Roy Debajyoti, Joan Khoo, Choon How How, and Alvin Kok Heong Ng. "Secondary Hypertension in Adults." Singapore Medical Journal 57, no. 5 (May 2016): 228–32. https://doi.org/10.11622/smedj.2016087.
  • Publishing, Harvard Health. "Medications for Treating Hypertension." Harvard Health. Accessed March 22, 2019. https://www.health.harvard.edu/heart-health/medications-for-treating-hypertension.
  • Ram, C. Venkata S. "Beta-Blockers in Hypertension." The American Journal of Cardiology 106, no. 12 (December 2010): 1819–25. https://doi.org/10.1016/j.amjcard.2010.08.023.
  • Rangaswami Janani, Bhalla Vivek, Blair John E.A., Chang Tara I., Costa Salvatore, Lentine Krista L., Lerma Edgar V., et al. "Cardiorenal Syndrome: Classification, Pathophysiology, Diagnosis, and Treatment Strategies: A Scientific Statement From the American Heart Association." Circulation 0, no. 0 (n.d.): CIR.0000000000000664. https://doi.org/10.1161/CIR.0000000000000664.
  • Renna, Nicolás F., Natalia de las Heras, and Roberto M. Miatello. "Pathophysiology of Vascular Remodeling in Hypertension." International Journal of Hypertension 2013 (2013): 1–7. https://doi.org/10.1155/2013/808353.
  • "Renovascular Hypertension - Cardiovascular Disorders - Merck Manuals Professional Edition." Accessed March 19, 2019. https://www.merckmanuals.com/professional/cardiovascular-disorders/hypertension/renovascular-hypertension.
  • Roush, George C., and Domenic A. Sica. "Diuretics for Hypertension: A Review and Update." American Journal of Hypertension 29, no. 10 (October 1, 2016): 1130–37. https://doi.org/10.1093/ajh/hpw030.
  • ———. "Diuretics for Hypertension: A Review and Update." American Journal of Hypertension 29, no. 10 (October 1, 2016): 1130–37. https://doi.org/10.1093/ajh/hpw030.
  • Shahin, Mohamed H, and Julie A Johnson. "Mechanisms and Pharmacogenetic Signals Underlying Thiazide Diuretics Blood Pressure Response." Current Opinion in Pharmacology 27 (April 2016): 31–37. https://doi.org/10.1016/j.coph.2016.01.005.
  • Siervo, Mario, Jose Lara, Shakir Chowdhury, Ammar Ashor, Clio Oggioni, and John C. Mathers. "Effects of the Dietary Approach to Stop Hypertension (DASH) Diet on Cardiovascular Risk Factors: A Systematic Review and Meta-Analysis." British Journal of Nutrition 113, no. 01 (January 2015): 1–15. https://doi.org/10.1017/S0007114514003341.
  • Soleimani, Manoocher. "Insulin Resistance and Hypertension: New Insights." Kidney International 87, no. 3 (March 1, 2015): 497–99. https://doi.org/10.1038/ki.2014.392.
  • Sonoyama, Kazuhiko, Adam Greenstein, Anna Price, Kaivan Khavandi, and Tony Heagerty. "Vascular Remodeling: Implications for Small Artery Function and Target Organ Damage." Therapeutic Advances in Cardiovascular Disease 1, no. 2 (December 2007): 129–37. https://doi.org/10.1177/1753944707086358.
  • Sug, Sung. "Hypertension Prevalence and Control Among Adults: United States, 2011–2014," no. 220 (2015): 8.
  • Sumners, Colin, Annette D. de Kloet, Eric G. Krause, Thomas Unger, and U. Muscha Steckelings. "Angiotensin Type 2 Receptors: Blood Pressure Regulation and End Organ Damage." Current Opinion in Pharmacology 21 (April 2015): 115–21. https://doi.org/10.1016/j.coph.2015.01.004.
  • Sun Zhongjie. "Aging, Arterial Stiffness, and Hypertension." Hypertension 65, no. 2 (February 1, 2015): 252–56. https://doi.org/10.1161/HYPERTENSIONAHA.114.03617.
  • Tam, Wilson, Susanna S. Ng, Kin‐Wang To, Fanny W. Ko, and David S. Hui. "The Interaction between Hypertension and Obstructive Sleep Apnea on Subjective Daytime Sleepiness." The Journal of Clinical Hypertension 21, no. 3 (March 2019): 390–96. https://doi.org/10.1111/jch.13485.
    te Riet Luuk, van Esch Joep H.M., Roks Anton J.M., van den Meiracker Anton H., and Danser A.H. Jan.
    "Hypertension." Circulation Research 116, no. 6 (March 13, 2015): 960–75. https://doi.org/10.1161/CIRCRESAHA.116.303587.
  • "The Hypertension Treatment Algorithm Made Simple." American Medical Association. Accessed March 22, 2019. https://www.ama-assn.org/delivering-care/hypertension/hypertension-treatment-algorithm-made-simple.
  • "Types of Blood Pressure Medications." www.heart.org. Accessed March 22, 2019. https://www.heart.org/en/health-topics/high-blood-pressure/changes-you-can-make-to-manage-high-blood-pressure/types-of-blood-pressure-medications.
  • "Vasopressin, Central Autonomic Control and Blood Pressure Regulation - ProQuest." Accessed March 13, 2019. https://search.proquest.com/openview/f6d0d68bf825c44f50bd2e5fc0412c7c/1.pdf?pq-origsite=gscholar&cbl=326347.
  • Viera, Anthony J., and Dana Neutze. "Diagnosis of Secondary Hypertension: An Age-Based Approach." American Family Physician 82, no. 12 (December 15, 2010): 1471–78.
  • Whelton, Paul K., Robert M. Carey, Wilbert S. Aronow, Donald E. Casey, Karen J. Collins, Cheryl Dennison Himmelfarb,
    Sondra M. DePalma, et al. "2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults." Journal of the American College of Cardiology 71, no. 19 (May 2018): e127–248. https://doi.org/10.1016/j.jacc.2017.11.006.
  • Wiysonge, Charles S, Hazel A Bradley, Jimmy Volmink, Bongani M Mayosi, and Lionel H Opie. "Beta-Blockers for Hypertension." The Cochrane Database of Systematic Reviews, no. 1 (January 20, 2017). https://doi.org/10.1002/14651858.CD002003.pub5.
  • Wright, James M, Vijaya M Musini, and Rupam Gill. "First-Line Drugs for Hypertension." Edited by Cochrane Hypertension Group. Cochrane Database of Systematic Reviews, April 18, 2018. https://doi.org/10.1002/14651858.CD001841.pub3.